October 2024 – Page 7

Poseida Therapeutics Advances Non-Viral Gene Editing Therapy for Hereditary Angioedema

1 year ago talkbio0Tagged Angioedemas, Hereditary, Cas-CLOVER, liver-directed gene therapy, non-viral gene, Poseida

Poseida Therapeutics, non-viral gene editing, hereditary angioedema (HAE), P-KLKB1-101, Cas-CLOVER, liver-directed gene therapy

Marinus Pharmaceuticals to Reduce Workforce and Explore Strategic Alternatives Following Disappointing Trial Results

1 year ago talkbio0Tagged Biotech Layoffs, Drug Industry, Marinus Pharmaceuticals, strategic alternatives, Ztalmy trial

Marinus Pharmaceuticals, workforce reduction, strategic alternatives, Ztalmy trial, pharmaceutical industry, biotech layoffs

Thermo Fisher Forecasts Revenue Growth in 2025 Amid Easing Market Challenges

1 year ago talkbio0Tagged 2025, Analytical Instruments, Growth, headwinds, Laboratory Products, pharmaceutical sector, Thermo Fisher Scientific

Thermo Fisher Scientific, revenue forecast, 2025 growth, easing headwinds, biotech funding, pharmaceutical sector, laboratory products, analytical instruments.

Roche CEO Urges Antitrust Regulators to Block Novo Holdings’ Acquisition of Catalent

1 year ago talkbio0Tagged Acquisitions, Catalent, Drug Industry, Holdings, mergers, Regulators (device), Roche (company)

Novo Holdings, Catalent, Roche, Antitrust Regulators, Pharmaceutical Industry, Mergers and Acquisitions

Roche Revisits Dyno for AAV Technology with $50M Upfront Payment

1 year ago talkbio0Tagged AAV, AAVS1 gene, Dyno, gene therapy, Neurological diseases, Roche (company), strategic partnership, Technology

Roche, Dyno Therapeutics, AAV technology, gene therapy, neurological diseases, strategic partnership

Pfizer Announces Additional Layoffs in North Carolina Following DMD Trial Setback

1 year ago talkbio0Tagged cost-cutting measures, gene therapy, Muscular Dystrophy, Duchenne, North Carolina, Pfizer Layoffs, Trial failure

Pfizer layoffs, North Carolina, Duchenne muscular dystrophy (DMD), gene therapy trial failure, cost-cutting measures

Ocuphire Pharma Acquires Opus Genetics, Expanding into Inherited Retinal Disease Gene Therapies

1 year ago talkbio0Tagged Acquisition, Biological Factors, gene therapy, Hereditary, IRDs, Ocuphire Pharma, ophthalmic treatments, Opus, Retinal Diseases, Science of genetics

Ocuphire Pharma, Opus Genetics, gene therapy, inherited retinal diseases (IRDs), merger, acquisition, biopharmaceutical, ophthalmic treatments

Alpha-9 Radios Secures $175M Funding for RLT Portfolio Advancement

1 year ago talkbio0Tagged Alpha-9, Investments, portfolio, Radio communications, Radiopharmaceuticals, RLT

Alpha-9 radios, $175M funding, RLT portfolio, radiopharmaceuticals, biotech investment

Vabysmo’s Growth Pace Slows in Q3, Still on Track for Dominance in Eye Disease Market

1 year ago talkbio0Tagged Age related macular degeneration, Macular edema due to diabetes mellitus, Market, Regeneron, Roche (company), Vabysmo, Vascular Endothelial Growth Factor A

Vabysmo, Roche, Regeneron, Eylea HD, eye disease market, vascular endothelial growth factor A (VEGF-A) therapy, age-related macular degeneration (AMD), diabetic macular edema (DME).

NICE Rejects Alzheimer’s Drug Kisunla Despite UK Regulatory Approval

1 year ago talkbio0Tagged Alzheimer 's disease, Cost-Effectiveness, Donanemab, Eli, Eli Lilly, Kisunla, MHRA, Nance-Horan syndrome, NHS, Nitroglycerin/Sodium Citrate/Ethanol Solution

NICE, Alzheimer’s disease, donanemab, Kisunla, Eli Lilly, MHRA, NHS, cost-effectiveness